SARS-CoV-2 pseudovirus
一、Product Introduction
Pseudovirus
|
Product name
|
report gene
|
specifications
|
Wild type COVID-19 S protein pseudovirus
|
SARS-CoV-2 Spike Pseudovirus
|
GFP
|
≥1X10^8 IU/ml,1ml
|
Mutant COVID-19 S protein pseudovirus
|
SARS-CoV-2 Spike（D614G）Pseudovirus
|
GFP
|
≥1X10^8 IU/ml,1ml
|
二、 Product Overview
In order to facilitate the research and development of COVID-19 drugs and vaccines, Vivo successfully prepared COVID-19 S protein pseudovirus by replacing the envelope protein vesicular stomatitis virus G glycoprotein (VSV-G) in the lentivirus packaging system with the SARS CoV-2 Spike glycoprotein.
三、Product features
1. High safety, able to operate directly in BSL-2 level laboratories, reducing exposure risks;
2. Can effectively infect target cells expressing ACE2, facilitating virus infection verification;
3. Carry GFP reporter gene for easy observation and detection in the future;
4.Target genes can be customized according to customer experimental needs.
四、Product application
1. Detection of neutralizing antibody levels against SARS-CoV-2;
2. Development and efficacy evaluation of vaccines and drugs against SARS-CoV-2 infection;
3.Research on the interaction mechanism of virus receptors, etc.
五、Data support
1. Validation of the infectivity of wild-type SARS-CoV-2 S protein pseudovirus
2.Validation of the infectivity of mutant SARS-CoV-2 (D614G) pseudovirus
The infectivity of wild-type and mutant pseudoviruses was validated using 293T-ACE2 monoclonal cells. 293T cells were used as controls, and fluorescence observation at 48 hours showed that both could specifically infect 293T-ACE2 monoclonal cell lines, indicating successful preparation of pseudovirus packaging. In addition, the mutant SARS CoV-2 (D614G) pseudovirus has a stronger infectivity than the wild type SARS CoV-2 pseudovirus in the same volume and infection time, which is consistent with the research report that the mutation of S protein D614G will enhance the infectivity of COVID-19.
